Menu Search
Equities

PCI Biotech Holding ASA

4QG:BER

PCI Biotech Holding ASA

Actions
  • Price (EUR)0.1496
  • Today's Change-0.004 / -2.60%
  • Shares traded--
  • 1 Year change+11.31%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:43 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in NOKIncome statement in NOKView more

Year on year PCI Biotech Holding ASA had revenues fall -37.05% from 4.75m to 2.99m, though the company grew net income from a loss of 55.10m to a smaller loss of 20.32m.
Gross margin--
Net profit margin-266.74%
Operating margin-296.63%
Return on assets-35.59%
Return on equity-40.61%
Return on investment-40.42%
More ▼

Cash flow in NOKView more

In 2023, cash reserves at PCI Biotech Holding ASA fell by 15.41m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 14.97m for operations while cash used for financing totalled 442.00k.
Cash flow per share-0.4197
Price/Cash flow per share--
Book value per share0.8548
Tangible book value per share0.8548
More ▼

Balance sheet in NOKView more

PCI Biotech Holding ASA appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio6.86
Quick ratio--
Total debt/total equity0.0149
Total debt/total capital0.0147
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.